TIDMSBI
RNS Number : 6808K
SourceBio International PLC
09 May 2022
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Po sting of Annual Report and Accounts
and Notice of Annual General Meeting
SourceBio International plc (AIM: SBI), a leading international
provider of integrated state-of-the-art laboratory services and
products , c onfirms that the Annual Report and Accounts for the
year ended 31 December 2021 ("2021 Annual Report") and Notice of
the 2022 Annual General Meeting ("AGM") have now been published on
the Company's website at: https://www.sourcebiointernational.com
(under Investor Relations, General Meetings section).
The 2021 Annual Report, and the Notice of AGM, which includes
details of voting by proxy, will be posted to shareholders who have
not consented to receive electronic communications.
The AGM is to be held on 15 June 2022 at midday at the Company's
offices at 1 Orchard Place, Nottingham Business Park, Nottingham,
NG8 6PX and will consider the resolutions set out in the Notice of
AGM.
The minimum number of Directors who hold shares will be present,
to form the necessary quorum. Regrettably, other shareholders will
not be permitted to attend the meeting in person.
The Company will provide a facility for shareholders to listen
in to the AGM either online or telephonically (in a non voting
capacity) via the Investor Meet Company ("IMC") platform and there
will be an opportunity for shareholders to ask questions. In order
to facilitate the process, the Directors would request that
shareholders register for the meeting and submit questions in
advance, before 5pm on 11 June 2022. Investors can sign up for IMC
for free and add to meet SourceBio International via:
https://investormeetcompany.com/sourcebio-international-plc/register-investor
Investors who have already registered for the IMC platform and
added to meet the Company will be automatically invited.
Proxy voting
Shareholders wishing to vote on any of the matters of business
are strongly encouraged to appoint the Chairman of the Meeting as
their proxy. If you attempt to appoint a named individual other
than the Chairman of the Meeting, such individual will not be
permitted to attend the Meeting and you will instead be deemed to
have appointed the Chairman of the Meeting as your proxy.
Shareholders will receive a hard copy form of proxy for the 2022
AGM in the post and may also appoint a proxy by submitting a
completed form of proxy to the Company's registrar online at
sharevote.co.uk. Alternatively, shareholders are able to appoint a
proxy via the CREST system. For your vote to be valid, please
ensure it is received no later than midday on 13 June 2022. For
more information on voting by proxy, including electronically or
via CREST, please refer to the Explanatory Notes in the Notice of
AGM.
Shareholders may request additional proxy forms directly from
the Registrars, Equiniti, on Tel: 0371 384 2030 (+44 (0)121 415
7047 if calling from outside the UK). Calls are charged at the
standard geographic rate and will vary by provider. Calls outside
the United Kingdom will be charged at the applicable international
rate. Shareholders wishing to appoint a proxy are strongly
encouraged to appoint the Chairman of the Meeting as their
proxy.
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Advisor and Broker) Tel: 020 3100 2000
Richard Lindley / William Hall
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502
558 258
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four business units:
-- Healthcare Diagnostics - histopathology cancer screening and
clinical diagnostic services for the NHS and private healthcare
providers across the UK and Ireland, including Digital
Pathology
-- Genomics - DNA sequencing services and Precision Medicine
offering for pharmaceutical and biotechnology companies, academia,
contract research organisations (CROs) and other research groups in
the UK, Europe and North America
-- Stability Storage - shelf-life testing services and equipment
service and validation for pharmaceutical and biotechnology
companies, contract manufacturers and analytical testing companies
from around the world but primarily in the UK, Ireland and the
USA
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups and
the NHS, including PCR testing under ISO 15189 accreditation.
SourceBio also provides employee testing solutions to industry,
direct to consumer home test kits and venue testing.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAMZGGKVVVGZZM
(END) Dow Jones Newswires
May 09, 2022 13:10 ET (17:10 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024
